Načítá se...
Utilization of Biomarkers in Lupus Nephritis
Lupus nephritis (LN), occurs in up to 60% of SLE patients, and is a leading cause of disability and death. Current treatment of LN consists of a combination of high dose corticosteroids that non-specifically decrease inflammation and cytotoxic medications that reduce autoantibody production. That co...
Uloženo v:
| Vydáno v: | Adv Chronic Kidney Dis |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7001747/ https://ncbi.nlm.nih.gov/pubmed/31733719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.ackd.2019.09.001 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|